Sunvozertinib for advanced EGFR-mutated lung cancer after treatment failure
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new pill called sunvozertinib in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to earlier treatments. The goal is to see how well it works and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of lung cancer called non-squamous non-small cell lung cancer (not squamous).
- Your tumor has a specific EGFR mutation (exon 19 deletion or L858R).
- You have already tried an EGFR inhibitor (like erlotinib, gefitinib, or osimertinib) and also chemotherapy, but the cancer has kept growing.
- You have at least one tumor that can be measured on scans.
- You do not have spinal cord compression, cancer spread to the meninges, or certain other serious conditions like recent stroke or bleed in the brain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new pill (sunvozertinib) combined with chemotherapy for people with a specific EGFR mutation type of lung cancer whose previous targeted pill stopped working. It aims to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two targeted pills (sunvozertinib and anlotinib) as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if this combination works better than current standard treatments.
This trial tests a drug called sunvozertinib in people with advanced non-small cell lung cancer (NSCLC) that has not been treated yet. It is for those who have certain uncommon changes in the EGFR gene. The drug may shrink tumors or stop them from growing.
This trial tests a combination of two oral drugs (sunvozertinib and anlotinib) as a first treatment for advanced lung cancer with certain EGFR mutations plus other gene changes. It aims to see if this combination works better than standard treatments.
This trial tests the drug sunvozertinib given after surgery to see if it prevents lung cancer from coming back. It is for people with early-stage non-small cell lung cancer that has specific changes in the EGFR gene (exon20 insertion or PACC mutations).
This trial tests a new combination of two oral targeted drugs for people with advanced non-small cell lung cancer that has an EGFR mutation. It may help if you have already been treated with a third-generation EGFR pill or if you are starting treatment for the first time.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.